SEB Nordic Future Opportunity C EURRegister to Unlock Ratings |
Performance History | 31/03/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 21.4 | 24.2 | -12.7 | 1.5 | 5.0 | |
+/-Cat | -3.3 | 7.8 | 0.9 | -6.5 | 0.7 | |
+/-B’mrk | -1.7 | 3.9 | -4.0 | -12.3 | -1.5 | |
Category: Nordic Equity | ||||||
Category Benchmark: Morningstar Nordic TME NR EUR |
Key Stats | ||
NAV 22/04/2024 | EUR 19.54 | |
Day Change | 0.69% | |
Morningstar Category™ | Nordic Equity | |
ISIN | LU0030165871 | |
Fund Size (Mil) 22/04/2024 | EUR 219.52 | |
Share Class Size (Mil) 22/04/2024 | SEK 64.12 | |
Max Initial Charge | - | |
Ongoing Charge 09/04/2024 | 1.25% |
Investment Objective: SEB Nordic Future Opportunity C EUR |
To increase the value of your investment over time while seeking to create a positive environmental and social impact to achieve, inter alia, the long-term objectives of the Paris Agreement, VINX Benchmark Cap Net Return Index, a measure of performance of Nordic companies that does not take into account ESG factors and is not aligned with the sustainable objective of the sub-fund. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Caroline Forsberg 07/09/2022 | ||
Robert Vicsai 07/09/2022 | ||
Inception Date 06/12/1988 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ VINX Benchmark Cap NR SEK | Morningstar Nordic TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for SEB Nordic Future Opportunity C EUR | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk A/S Class B | Healthcare | 9.60 |
Hexagon AB Class B | Technology | 5.93 |
Atlas Copco AB Class A | Industrials | 4.97 |
AstraZeneca PLC | Healthcare | 4.92 |
Addtech AB Class B | Industrials | 3.23 |
Increase Decrease New since last portfolio | ||
SEB Nordic Future Opportunity C EUR |